Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Pei Zhang(Chinese Academy of Sciences), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College)
BMC Medicine
November 9, 2022
Cited by 36


Related Papers